By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
TYSABRI441.5M17.82%
Revenue from anti-CD20 therapeutic programs419.1M16.91%
SPINRAZA374M15.09%
Other271.8M10.97%
Contract manufacturing, royalty and other revenue246.9M9.96%
VUMERITY179M7.22%
AVONEX163.2M6.59%
SKYCLARYS150.7M6.08%
BENEPALI122.1M4.93%
TECFIDERA109.5M4.42%
View all
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
U.S.5.74B58.01%
Europe1.88B19.05%
Germany853M8.62%
Asia726.5M7.35%
Other511.2M5.17%
Alzheimer's collaboration revenue177.7M1.80%
View all